Avastin, Alimta — Competitive Intelligence Brief

Avastin, Alimta (Avastin, Alimta) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Oncology.

phase 2 monoclonal antibody VEGF Oncology Small molecule

Target snapshot

Avastin, Alimta (Avastin, Alimta) — The Cooper Health System. Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Avastin, Alimta TARGET	Avastin, Alimta	The Cooper Health System	phase 2	monoclonal antibody	VEGF
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
PAZOPANIB HYDROCHLORIDE	PAZOPANIB HYDROCHLORIDE		marketed		VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

1. Pfizer · 3 drugs in this class
2. Avalo Therapeutics, Inc. · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class
4. Celltrion · 1 drug in this class
5. Centocor, Inc. · 1 drug in this class
6. Clinique des Céphalées de Montréal · 1 drug in this class
7. Dermira, Inc. · 1 drug in this class
8. European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
9. Gliknik Inc. · 1 drug in this class
10. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class